REG - IXICO plc - PDMR Exercise of Options

IXICOAnnouncement

13/12/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221213:nRSM4375Ja&default-theme=true

RNS Number : 4375J  IXICO plc  13 December 2022

13 December 2022

IXICO plc

("IXICO" or the "Company")

 

PDMR Exercise of Options

IXICO plc (AIM: IXI), the precision analytics company delivering intelligent
insights in neuroscience, announces that it received notification on 12
December 2022 that Grant Nash, CFO and PDMR, exercised 200,000 share options
with an exercise price of 1p.  Following this transaction Grant Nash holds
200,000 shares in IXICO.

 

Application has been made to the London Stock Exchange for the admission to
trading on AIM the 200,000 new ordinary shares of 1p each ("New Shares") to
satisfy the exercise of options. The New Shares are expected to be admitted to
trading on AIM on 16 December 2022.

 

Total voting rights

 

Application has been made for admission to trading on AIM of 200,000 New
Shares. Following Admission of the New Shares on AIM there will be in total
48,351,373 ordinary shares in the capital of the Company in issue, each
carrying equal voting rights.

 

This figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to notify their
interest in, or a change to their interest in, IXICO under the FCA's
Disclosure and Transparency Rules.

 

Details of PDMR transaction

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Grant Nash

 2    Reason for the notification

 a)   Position/status                                              PDMR (CFO)

 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         IXICO plc

 b)   LEI                                                          2138005M1F59O6HWSA97

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Ordinary Shares in IXICO plc

      Identification code                                          GB00BCLY7L40

 b)   Nature of the transaction                                    Exercise of options over ordinary shares

 c)   Price(s) and volume(s)

                                                                                     Exercise Price(s)  Volume(s)
                                                                                     1p                 200,000

 d)   Aggregated information

      - Aggregated volume                                          n/a

      - Price

 e)   Date of the transaction                                      12 December 2022

 f)   Place of the transaction                                     N/A

 

For further information please contact:

 

 IXICO plc                                         +44 (0)20 3763 7499
 Giulio Cerroni, Chief Executive Officer

 Grant Nash, Chief Financial Officer

 Cenkos Securities PLC (Nominated adviser and sole broker)                         +44 (0)20 7397 8900
 Giles Balleny / Max Gould (Corporate Finance)
 Michael F Johnson / Tamar Cranford-Smith (Sales)

IXICO is dedicated to delivering insights in neuroscience to help transform
the advancement of investigational therapies for neurological diseases, such
as Huntington's, Parkinson's, Alzheimer's disease and Multiple Sclerosis. The
Company's purpose is to advance medicine and human health by turning data into
clinically meaningful information, providing valuable new insights in
neuroscience by supporting pharmaceutical companies across all phases of CNS
clinical research. IXICO's goal is to be a leading advocate of artificial
intelligence in medical image analysis.

 

IXICO has developed and deployed breakthrough machine learning AI data
analytics, at scale, through its remote access TrialTracker technology
platform, to improve the return on investment in drug development and reduce
risk and uncertainty in clinical trials for the Company's pharmaceutical
clients.

 

 

More information is available on www.IXICO.com (http://www.IXICO.com) and
follow us on Twitter @IXICOnews

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHFFWFMEEESELE